Pioneering a New Era of Gene Therapy. We are developing Anellovectors™, the first potentially redosable and targetable gene therapy platform, by harnessing the human commensal virome.
Member count: 11-50
Total raised: $203.5M
Founded date: 2017
Investors 1
| Date | Name | Website |
| - | Altitude L... | altitudels... |
Funding Rounds 2
| Date | Series | Amount | Investors | Deal News |
| 09.03.2023 | Series C | $86.5M | - | finsmes.co... |
| 28.07.2021 | Series B | $117M | - | fiercebiot... |
Mentions in press and media 6
| Date | Title | Description | Category | Author | Source |
| 09.03.2023 | Ring Thera... | Ring Therapeutics, a Cambridge... | USA | - | finsmes.co... |
| 09.03.2023 | Ring Thera... | - | - | - | globenewsw... |
| 28.07.2021 | TPG and Br... | As interest in climate-tech gr... | - | - | fortune.co... |
| 28.07.2021 | Ring Thera... | Ring Therapeutics, a Cambridge... | USA | - | finsmes.co... |
| 28.07.2021 | TPG and Br... | This is the web version of Ter... | - | - | fortune.co... |
| 28.07.2021 | Ring Thera... | Gene therapies come with a ros... | Biotech | - | fiercebiot... |